Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Trump Media and Technology Group Corp (DJT) vs Cassava Sciences Inc (FLNA) Price & Performance

Trump Media and Technology Group CorpTrade
Cassava Sciences IncTrade

Price performance (Past 24H)

Key statistics

Trump Media and Technology Group Corp vs Cassava Sciences Inc — how do they compare? Trump Media and Technology Group Corp trades at $9.37 (market cap $2.50B), while Cassava Sciences Inc trades at $1.11 (market cap $52.66M). The key difference: Trump Media and Technology Group Corp is far larger — about 47.5× Cassava Sciences Inc's market cap, and Trump Media and Technology Group Corp is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.

DJTFLNA
Market Cap
$2.50B$52.66M
Sector
MediaHealth
52-Week High
$19.86$4.64
52-Week Low
$7.06$1.09
Enterprise Value
$2.45B-$33.92M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Trump Media and Technology Group Corp

DJT trades at $8.52, down 0.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported minimal revenue of $3.68M in 2025 alongside a massive net loss of -$712.06M, reflecting severe profitability challenges. Recent news highlights a nearly 50% stock decline in 2026 and the cancellation of a Truth Social spin-off, while a merger with TAE Technologies aims to pivot toward nuclear fusion energy.

The outlook remains highly speculative, with the stock's meme-driven volatility and fundamental weaknesses posing significant risks. Investment opportunity hinges on successful execution of the TAE merger and fusion technology prospects, but persistent losses and high valuation ratios suggest substantial downside potential if growth fails to materialize.

Cassava Sciences Inc

FLNA trades at $1.15, down 2.54% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company continues to report losses, with a net income of -$90.97M in 2025 and negative cash flow, though it has beaten EPS estimates for the last three quarters. Recent news highlights ongoing development in its TSC-related epilepsy therapies.

Despite consistent earnings beats, FLNA's negative profitability and cash burn pose significant risks. Analyst sentiment is positive with a 66.7% buy rating, but the stock's outlook depends heavily on clinical success and future funding. Investors should weigh the high-risk, high-reward nature of this biotech play.

Returns comparison

Trailing returns across standard periods

About Trump Media and Technology Group Corp

Trump Media & Technology Group is a media firm rooted in social media and digital streaming. Its flagship product, Truth Social, provides a platform focused on free speech and open conversation.

Read more on DJT

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA